Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial,The Lancet Oncology

当前位置： X-MOL 学术 › Lancet Oncol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial
The Lancet Oncology ( IF 41.6 ) Pub Date : 2024-08-12 , DOI: 10.1016/s1470-2045(24)00338-3
Emanuel Bührer ₁ , Michal Kicinski ₁ , Mario Mandala ₂ , Madeline Pe ₁ , Georgina V Long ₃ , Victoria Atkinson ₄ , Christian U Blank ₅ , Andrew Haydon ₆ , Stéphane Dalle ₇ , Adnan Khattak ₈ , Matteo S Carlino ₉ , Andrey Meshcheryakov ₁₀ , Shahneen Sandhu ₁₁ , Susana Puig ₁₂ , Dirk Schadendorf ₁₃ , Rahima Jamal ₁₄ , Piotr Rutkowski ₁₅ , Alfonsus J M van den Eertwegh ₁₆ , Corneel Coens ₁ , Dmitri Grebennik ₁₇ , Clemens Krepler ₁₇ , Caroline Robert ₁₈ , Alexander M M Eggermont ₁₉

Affiliation

European Organisation for Research and Treatment of Cancer (EORTC) Headquarters, Brussels, Belgium.
University of Perugia, Santa Maria Misericordia Hospital, Perugia, Italy.
Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia; Mater and Royal North Shore Hospitals, Sydney, NSW, Australia.
Princess Alexandra Hospital, University of Queensland, Brisbane, QLD, Australia.
Netherlands Cancer Institute, Amsterdam, Netherlands.
Department of Medical Oncology, Alfred Hospital, Melbourne, VIC, Australia.
Hospices Civils de Lyon, Pierre Bénite, Cancer Research Center of Lyon, Lyon, France.
Fiona Stanley Hospital and Edith Cowan University, Perth, WA, Australia.
Westmead and Blacktown Hospitals, Melanoma Institute Australia, The University of Sydney, Westmead, NSW, Australia.
Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency, Moscow, Russia.
Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Dermatology Department, Hospital Clínic Barcelona, University of Barcelona and CIBERER, Instituto de Salud Carlos III, Barcelona, Spain.
University Hospital Essen, Essen and German Cancer Consortium, Essen, Germany; National Center for Tumor Diseases (NCT-West), Campus Essen and Research Alliance Ruhr, Research Center One Health, University Duisburg, Essen, Germany.
Centre Hospitalier de l'Université de Montréal (CHUM), Centre de Recherche du CHUM, Montreal, QC, Canada.
Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
Department of Medical Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, Netherlands.
Merck, Rahway, NJ, USA.
Gustave Roussy Cancer Campus Grand Paris and University Paris-Saclay, Villejuif, France.
Comprehensive Cancer Center Munich of the Technical University Munich and the Ludwig Maximiliaan University, Munich, Germany; Princess Máxima Center and University Medical Center Utrecht, Utrecht, Netherlands.

In the European Organisation for Research and Treatment of Cancer (EORTC) 1325-MG/KEYNOTE-054 study, adjuvant pembrolizumab improved recurrence-free survival and distant-metastasis-free survival in patients with resected stage III melanoma. Earlier results showed no effect of pembrolizumab on health-related quality of life (HRQOL). Little is known about HRQOL after completion of treatment with pembrolizumab, an important research area concerning patients who are likely to become long-term survivors. This study reports long-term HRQOL results.

中文翻译：

帕博利珠单抗辅助与安慰剂在切除的 III 期黑色素瘤（EORTC 1325-MG/KEYNOTE-054）中的比较：来自双盲、随机、对照、3 期试验的长期、与健康相关的生活质量结果

在欧洲癌症研究与治疗组织（EORTC） 1325-MG/KEYNOTE-054 研究中，帕博利珠单抗辅助治疗提高了已切除的 III 期黑色素瘤患者的无复发生存期和无远处转移生存期。早期结果显示 pembrolizumab 对健康相关生活质量（HRQOL）没有影响。对完成 pembrolizumab 治疗后的 HRQOL 知之甚少，这是一个关于可能成为长期幸存者的患者的重要研究领域。本研究报告了长期 HRQOL 结果。

更新日期：2024-08-12

点击分享查看原文

点击收藏

阅读更多本刊新发论文